Basel

Banco Santander-Chile Announces Third Quarter 2023 Earnings

Retrieved on: 
Tuesday, October 31, 2023
Banco Santander Chile, LCR, SME, Insurance, SSE, MPR, Yoy, Moody's Investors Service, Bank, Index, NYSE, NPL, ESG, BIS, Basel, S&P Global Ratings, Government, ADR, Getnet Wale, KBRA, Investment banking, NPS, Corporation, Quarter, NII, Japan Credit Rating Agency, Acceleration, Life, Retail banking, Central Bank of Myanmar, Growth, Central bank, RWA, MIN, Travel, CLP, Depreciation, BSAC, Credit, CIB, Investment, YTD, UF, JPY, COVID-19, Rare-earth element, Cryptocurrency

SANTIAGO, Chile, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its resultsi for the nine-month period ended September 30, 2023, and third quarter 2023 (3Q23).

Key Points: 
  • SANTIAGO, Chile, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Banco Santander Chile (NYSE: BSAC; SSE: Bsantander) announced today its resultsi for the nine-month period ended September 30, 2023, and third quarter 2023 (3Q23).
  • During the third quarter of 2023, the Central Bank began to cut the MPR from 11.25% to 10.25% at the end of July to 9.50% in September.
  • Our earnings webcast will be held on Friday, November 3, 2023 at 10am New York time.
  • The BIS capital ratio as of September 30, 2023, was 17.1%, with a core capital ratio of 10.7%.

Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent

Retrieved on: 
Tuesday, October 31, 2023
KOSDAQ, Trial of the century, South Korea, MSSA, Bacteriophage, Biofilm, Intron, Gram-positive bacteria, Infection, Virus, Exercise, Biotechnology, A-DNA, Antimalarial medication, MRSA, LR, Bacteria, Korea, Patient, Death, Pharmaceutical industry, Vaccine, Basel, Allschwil

Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.

Key Points: 
  • Tonabacase is a potential first-in-class clinical-stage antibacterial of the endolysin class.
  • Over the course of 2024, Basilea will investigate various hypotheses in a number of preclinical studies to determine the optimal future clinical development program for tonabacase.
  • Upon successful completion of the preclinical evaluation phase, Basilea will have the exclusive option to license tonabacase for further clinical development and commercialization.
  • This transaction has no impact on Basilea’s financial guidance for 2023, provided on August 15, 2023.

iNtRON, Executes Evaluation License and Option Agreement for SAL200

Retrieved on: 
Tuesday, October 31, 2023
Infection, US, Intron, Basel, Biotechnology, Probability, NDA, Fungal infection, Pharmaceutical industry, Allschwil

BOSTON and SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that they have signed an "EVALUATION LICENSE AND OPTION AGREEMENT" with Basilea Pharmaceutica Ltd, Allschwil ("Basilea"), granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200 (Tonabacase).

Key Points: 
  • BOSTON and SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com ) has announced today that they have signed an "EVALUATION LICENSE AND OPTION AGREEMENT" with Basilea Pharmaceutica Ltd, Allschwil ("Basilea"), granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200 (Tonabacase).
  • iNtRON will receive an initial upfront payment upon the execution of this agreement and will receive an additional payment upon Basilea exercising the option to negotiate an exclusive license agreement after the completion of the evaluation test, which can last up to one year.
  • Certain essential terms of the exclusive license agreement have been pre-agreed upon along with the current agreement.
  • iNtRON has been actively discussing the exclusive license agreement with Basilea, who showed keen interest in SAL200.

BANKFIRST CAPITAL CORPORATION Reports Third Quarter 2023 Earnings of $8.4 Million

Retrieved on: 
Friday, October 27, 2023
Sale, FRB, Bank, Federal Home Loan Banks, Microenterprise Education Initiative, OTCQX, Acquisition, Bank First, Sycamore Bank, Federal Reserve Bank of St. Louis, Equitable, Community Development Financial Institutions Fund, Federal Reserve Bank, Environment, Community development financial institution, Mechanics Bank, Community development, Risk, Mechanics, Tate, CDFI, Community Facilities Program, Total, Visa requirements for Turkish citizens, ERP, Video game, Cryptocurrency, Rare-earth element, Basel

Net interest income increased 26% to $21.6 million in the third quarter of 2023 from $17.1 million in the third quarter of 2022.

Key Points: 
  • Net interest income increased 26% to $21.6 million in the third quarter of 2023 from $17.1 million in the third quarter of 2022.
  • Net interest income was $21.6 million for the third quarter of 2023, compared to $22.7 million for the second quarter of 2023, a decrease of 5%, and compared to $17.1 million for the third quarter of 2022, an increase of 26%.
  • Noninterest income was $10.1 million for the third quarter of 2023, compared to $6.1 million for the second quarter of 2023, an increase of 65%, and compared to $5.4 million for the third quarter of 2022, an increase of 87%.
  • Noninterest expense was $20.0 million for the third quarter of 2023, compared to $20.5 million for the second quarter of 2023 and $15.2 million for the third quarter of 2022, an decrease of 2.1% and an increase of 32.0%, respectively.

C&F Financial Corporation Announces Net Income for Third Quarter and First Nine Months

Retrieved on: 
Thursday, October 26, 2023
Consolidated, Car, Insurance, Sale, FDIC, Federal Deposit Insurance Corporation, Government, Share repurchase, GAAP, Federal Reserve Bank of St. Louis, Federal Reserve Bank, Corporate debt bubble, Environment, Growth, COVID-19, Employment, Current Expected Credit Losses, FHLB, Corporation, CECL, External commercial borrowing, Community, Investment, Bank, Cryptocurrency, Arms industry, Health care, Real estate, Reinsurance, Security (finance), Basel

Asset quality remains strong, although we are monitoring economic conditions and their impact on our borrowers’ financial positions.”

Key Points: 
  • Asset quality remains strong, although we are monitoring economic conditions and their impact on our borrowers’ financial positions.”
    Key highlights for the third quarter and first nine months of 2023 are as follows.
  • Average deposits increased $16.8 million, or less than one percent, for the third quarter of 2023 compared to the second quarter of 2023.
  • Management believes that the level of the allowance for credit losses is adequate to reflect the net amount expected to be collected.
  • During the third quarter of 2023, the Corporation repurchased 23,856 shares, or $1.3 million, of its common stock under this share repurchase program.

Capital City Bank Group, Inc. Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, October 24, 2023
Insurance, Sale, FDIC, CCHL, Bank, Federal Home Loan Banks, Acquisition, FED, Growth, NOW, Tangibility, Credit, HFI, Negotiation, O'Hara, U.S. Treasury, Real estate, Video game, Cryptocurrency, Security (finance), Basel

Our net interest margin for the third quarter of 2023 was 4.02%, a decrease of three basis points from the second quarter of 2023 and an increase of 71 basis points over the third quarter of 2022.

Key Points: 
  • Our net interest margin for the third quarter of 2023 was 4.02%, a decrease of three basis points from the second quarter of 2023 and an increase of 71 basis points over the third quarter of 2022.
  • We recorded a provision for credit losses of $2.4 million for the third quarter of 2023 compared to $2.2 million for the second quarter of 2023 and $2.1 million for the third quarter of 2022.
  • Noninterest income for the third quarter of 2023 totaled $20.2 million compared to $22.9 million for the second quarter of 2023 and $22.9 million for the third quarter of 2022.
  • Noninterest expense for the third quarter of 2023 totaled $41.6 million compared to $42.5 million for the second quarter of 2023 and $39.8 million for the third quarter of 2022.

New Survey of Small Business Owners Shows a Credit Crunch is Hindering Growth

Retrieved on: 
Wednesday, October 25, 2023
Finance, Business, Banking, Professional Services, Small Business, Squeeze, Goldman Sachs, Policy, Small business, Goldman, United States Chamber of Commerce, Basel, Tell, National Urban League, Bipartisan Policy Center, Federal Reserve, Face, Commerce, NAACP, Federal, Growth, Small Business Administration, Fed, SBA, Bank, Cryptocurrency, Real estate

A credit crunch has descended upon small business owners nationwide hindering their growth and causing some to say that if it continues, they’ll be forced to close altogether.

Key Points: 
  • A credit crunch has descended upon small business owners nationwide hindering their growth and causing some to say that if it continues, they’ll be forced to close altogether.
  • While 78% of all small business owners said it was difficult to access capital, the challenge is more pronounced among minority small business owners.
  • 81% of Hispanic small business owners and 85% of Black small business owners are concerned about their ability to access capital.
  • According to the Goldman Sachs 10,000 Small Businesses Voices survey, 81% of Hispanic small business owners and 85% of Black small business owners are concerned about their ability to access capital.

Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week

Retrieved on: 
Monday, October 16, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Short bowel syndrome, Pharmacokinetics, United European Gastroenterology, Weaning, Risk, Trial of the century, Safety, Survival, Bronchoscopic lung volume reduction, Colon, SBS, Growth, PS, Gambat Liver Transplant Center, Ironwood Pharmaceuticals, Patient, UEG, Infection, Medication, CIC, Parenteral nutrition, STARS, Nutrition, Quality of life, Pharmaceutical industry, Birth control, Ironwood, Basel

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week.

Key Points: 
  • Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a global GI-focused healthcare company, presented positive final data from the company’s Phase II STARS Nutrition program during United European Gastroenterology (UEG) Week.
  • PS reduction was observed as early as week four and was maintained until the end of the study.
  • Seventy-eight percent (78%) of patients gained one or more days off PS with all patients achieving clinical response.
  • “We welcome these results and are continuing to progress the apraglutide development in the SBS-IF program with a sense of urgency.”

Wolters Kluwer introduces OneSumX for Basel at major client conference

Retrieved on: 
Thursday, October 5, 2023
Professional Services, Technology, Software, Finance, Fintech, Banking, Accounting, Capital Requirements Regulation 2013, III, ESG, European, Risk management, Wolters, Risk, Software as a service, CRR, FRR, Wolters Kluwer, Basel II, CP, Basel III: Finalising post-crisis reforms, Conference, Cryptocurrency, Basel

OneSumX for FRR addresses the tactical and strategic needs of finance , risk management , performance, compliance and regulatory reporting teams at financial institutions.

Key Points: 
  • OneSumX for FRR addresses the tactical and strategic needs of finance , risk management , performance, compliance and regulatory reporting teams at financial institutions.
  • Notably, Wolters Kluwer technology and expertise enable compliance with Basel II, Basel III, Basel 3.1 and Basel IV implementation & reporting timelines, allowing teams to make timely, informed decisions to manage risk more effectively, and optimize revenues.
  • “OneSumX for Basel enables banks to be compliant with the complex Basel regulations with an integrated solution, utilizing our unique Regulatory Update Service.
  • Basel reporting is a vital component of this.”
    Demonstrations of the solution suite and the new capabilities will be available to attendees of the FRR Client Conference.

Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

Retrieved on: 
Monday, October 2, 2023
Improper integral, ASIA, Genomics, Lonza, Danaher, MBA, CCO, Business administration, Repligen, Repligen Corporation Award in Chemistry of Biological Processes, Growth, Bioprocess, Emlyon Business School, Fine chemical, Management, Basel, Chemistry

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately.

Key Points: 
  • WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately.
  • Prior to Cytiva, he worked for a combined 12 years with Lonza, advancing to Vice President Sales, Lonza Custom Manufacturing.
  • Mr. Loeillot joins Repligen from his most recent role as Chief Executive Officer (CEO) of Ascensus Specialties, a manufacturer of specialty chemicals for use in the life sciences and pharmaceutical markets.
  • Hunt, Chief Executive Officer at Repligen, said, “We are delighted to welcome Olivier to our team at Repligen.